The company will imminently start its third pivotal trial of PF-08634404.
ApexOnco Front Page
Recent articles
But the Day One deal is still 29% below where the shares stood at the start of this year.
The Rainfol-04 trial in platinum-sensitive ovarian cancer will start next year.
The company ditches lorigerlimab in prostate cancer.
New detalimogene bladder cancer data send the minnow’s stock up 47%.
The response rate jumps to 30% with higher doses of IMA402.
After more discontinuations, a new deal brings in fresh blood.
The CD70-targeting CTX131 heads for the scrapheap.
